Rhenium Re-188 P2045
Large Cell Neuroendocrine Carcinoma
Explore 9 assets in Large Cell Neuroendocrine Carcinoma →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
University of Maryland, Baltimore
Modality
protein_peptide
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02030184CT.gov Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Large Cell Neuroendocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rhenium Re-188 P2045 (this asset) | University of Maryland, Baltimore | P1/2 | CC · 47 |
| Ipilimumab | National Cancer Institute (NCI) | P2 | CCC |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Cabozantinib | National Cancer Institute (NCI) | P2 | CCC |
| Dexasone | AbbVie | P1/2 | CCC |
| [212pb]pb-mp0712 | Molecular Partners AG | P1/2 | CCC |
| [203Pb]Pb-MP0712 | Molecular Partners AG | P1/2 | CCC |
| Etoposide | Phanes Therapeutics | P1/2 | CC |
| Carboplatin | Oncology Center of Biochemical Education And Research | P1/2 | CC |
+3 more in the Large Cell Neuroendocrine Carcinoma cohort
Other indications for Rhenium Re-188 P2045
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuroendocrine Neoplasm | — | P1/2 | CCC · 48 |
| Small Cell Lung Carcinoma | — | P1/2 | CCC · 48 |
| Lung Neoplasm | — | P1/2 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rhenium Re-188 P2045 in Large Cell Neuroendocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rhenium-re-188-p2045-large-cell-neuroendocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →